^99mTc-CXCR4-L for Imaging of the Chemokine-4 Receptor Associated with Brain Tumor Invasiveness: Biokinetics, Radiation Dosimetry, and Proof of Concept in Humans

Table 2

Average equivalent and effective doses of ^99mTc-CXCR4-L calculated from six healthy volunteers (3 females and 3 males).

Target organ	Equivalent doses (mean ± SD) (mSv/MBq)
	Females	Males
Adrenals	(8.93 ± 1.31) E − 06	(8.38 ± 2.27) E − 06
Brain	(3.32 ± 0.25) E − 06	(3.54 ± 0.96) E − 06
Breasts	(3.02 ± 0.64) E − 04	(4.70 ± 0.26) E − 05
Gallbladder wall	(1.59 ± 0.48) E − 04	(1.00 ± 0.04) E − 04
LLI wall	(6.10 ± 0.64) E − 04	(6.10 ± 0.30) E − 04
Small intestine	(2.05 ± 0.21) E − 05	(1.71 ± 0.50) E − 05
Stomach wall	(1.87 ± 0.14) E − 04	(2.01 ± 0.47) E − 04
ULI wall	(3.30 ± 0.45) E − 05	(2.74 ± 0.80) E − 05
Heart wall	(5.26 ± 0.64) E − 05	(5.57 ± 0.53) E − 05
Kidneys	(3.13 ± 0.57) E − 05	(1.03 ± 0.89) E − 04
Liver	(1.41 ± 0.36) E − 04	(1.46 ± 0.16) E − 04
Lungs	(4.37 ± 0.90) E − 04	(4.71 ± 0.57) E − 04
Muscle	(5.81 ± 0.46) E − 06	(5.41 ± 1.56) E − 06
Ovaries	(5.63 ± 0.16) E − 04	(0.00 ± 0.00) E+00
Pancreas	(9.13 ± 0.12) E − 06	(8.35 ± 2.29) E − 06
Red marrow	(1.46 ± 0.01) E − 04	(1.67 ± 0.05) E − 04
Osteogenic cells	(2.68 ± 0.22) E − 05	(3.18 ± 0.09) E − 05
Skin	(6.57 ± 0.59) E − 06	(7.67 ± 0.25) E − 06
Spleen	(7.35 ± 0.80) E − 06	(7.02 ± 1.84) E − 06
Testes	(0.00 ± 0.00) E+00	(1.75 ± 0.07) E − 03
Thymus	(6.22 ± 0.77) E − 06	(5.63 ± 1.70) E − 06
Thyroid	(3.88 ± 0.36) E − 05	(5.45 ± 0.16) E − 05
Urinary bladder wall	(7.76 ± 1.15) E − 04	(4.06 ± 0.90) E − 04
Uterus	(1.52 ± 0.06) E − 05	(1.15 ± 0.38) E − 05
Effective dose (mSv/MBq)	(3.59 ± 0.29) E − 03	(4.24 ± 0.21) E − 03